Ipamorelin vs GHRP-2: How Two GH Peptides Compare

Ipamorelin and GHRP-2 are both growth hormone secretagogues that act on the ghrelin receptor, but they are not interchangeable. Ipamorelin produces a smaller, cleaner growth hormone pulse with almost no effect on cortisol, prolactin, or appetite, while GHRP-2 produces a stronger GH release along with measurable increases in cortisol, prolactin, and hunger.

That difference — selectivity versus raw potency — drives most of the practical comparison between these two peptides. Neither compound is FDA-approved for human use, and both are sold strictly for laboratory research.

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide developed in the 1990s to act as a selective growth hormone secretagogue. It binds the ghrelin receptor (GHS-R1a) in the pituitary and triggers a pulsatile release of growth hormone that resembles the body's natural rhythm.

The key selling point in research literature is selectivity. Ipamorelin releases GH without meaningfully raising cortisol, prolactin, or aldosterone, and it does not drive hunger the way most other secretagogues do.

Researchers who want a gentler, more targeted pulse often compare it against other secretagogues. A common example is ipamorelin vs sermorelin, where the main trade-off is pulse length and cost rather than side-effect profile.

What Is GHRP-2?

GHRP-2, also known as pralmorelin, is a hexapeptide secretagogue that acts on the same ghrelin receptor. It is generally described as more potent than GHRP-6 for GH release while causing less appetite stimulation than GHRP-6 — though it still stimulates hunger more than ipamorelin does.

GHRP-2 also activates pathways that raise cortisol and prolactin. That broader hormonal footprint is the main reason some researchers prefer ipamorelin despite its smaller GH peak.

Ipamorelin vs GHRP-2: Side-by-Side Comparison

Growth Hormone Release: Which Peptide Is Stronger?

GHRP-2 wins on raw GH output. In head-to-head research models, GHRP-2 typically produces a larger and sharper growth hormone spike than ipamorelin at comparable doses.

Ipamorelin wins on selectivity. Its growth hormone release comes without the accompanying cortisol and prolactin rise that GHRP-2 causes, and it does not trigger hunger in the same way.

GHRP-2 sits between ipamorelin and GHRP-6 in the secretagogue family. It releases more GH than GHRP-6 without the intense appetite spike, which is why a discussion of ipamorelin vs ghrp 6 often ends up comparing GHRP-2 as well.

Side Effects and Safety Considerations

Both peptides are research chemicals, not approved medicines. Human safety data is limited, and the long-term effects of either compound are unknown.

Effects most often reported in research and anecdotal accounts include:

• GHRP-2: increased appetite, elevated cortisol and prolactin, water retention, tingling or numbness in the hands, headache, and possible desensitization of the GH response with continuous use.
• Ipamorelin: generally described as mild — injection-site irritation, transient headache, and occasional fatigue.

Desensitization is a real concern with the more potent secretagogues. Continuous exposure can blunt the pituitary response over time, and ipamorelin has a reputation for being more forgiving than hexarelin, which is why ipamorelin vs hexarelin comparisons usually favor ipamorelin for longer research protocols.

Anyone considering these compounds should speak with a healthcare professional first. Purity varies widely between vendors, and unverified peptides carry contamination risks that no dosage calculation can offset.

Stacking With Other Compounds

Growth hormone secretagogues are more often studied alongside a GHRH analog than alongside each other, because the two classes act on different receptors. Pairing a ghrelin-receptor agonist with CJC-1295 is the classic example, and the debate around cjc-1295 vs ipamorelin is mostly about whether the GHRH analog's longer half-life justifies its higher cost.

Non-peptide options exist too. Anyone weighing ipamorelin vs mk-677 should understand that MK-677 is an oral ghrelin mimetic that raises growth hormone around the clock — which also means near-constant hunger and a different risk profile than a short-acting injectable peptide.

Bottom Line

• Ipamorelin releases growth hormone with minimal impact on cortisol, prolactin, and appetite, while GHRP-2 releases more GH and raises all three.
• GHRP-2 produces a stronger growth hormone pulse than ipamorelin at comparable research doses.
• Neither ipamorelin nor GHRP-2 is FDA-approved for human use in the United States.
• Desensitization is a bigger practical concern with GHRP-2 than with ipamorelin.
• These peptides should only be handled as research chemicals, with medical guidance and third-party-tested product.